eyenovia-logo 3
  • In the News
  • Presentations
  • Publications

Febuary 2018

MFDA to require only one late-stage study to support marketing application for Eyenovia’s MicroPine for myopia; shares up 2%

NEW YORK, Feb. 21, 2018 Eyenovia (EYEN +1.7%announces that the FDA has indicated that only one pivotal Phase 3 clinical trial evaluating MicroPine for the treatment of myopia (nearsightedness) will be required to support a U.S. marketing application.  Read more


Febuary 2018

MicroPine phase 3 trial for myopia to begin in 2019

NEW YORK, Feb. 21, 2018 (Healio’s Ocular Surgery News) — Eyenovia Inc. (“Eyenovia”), (NASDAQ:EYEN), The MicroPine program for the treatment of progressive myopia will begin a phase 3 pivotal study in 2019, according to a press release from Eyenovia.. Read more


February 2018

Eyenovia Raises $27 Million With Initial Public Stock Offering

NEW YORK—Eyenovia Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products, reported last week that it closed its initial public offering of 2,730,000 shares of its common stock.  Read more


 

January 2018

Eyenovia Advances MicroPine for Myopia into Phase III Clinical Development and Appoints Stanford Professor Dr. Douglas Fredrick to its Scientific Advisory Board and Myopia Program Steering Committee

NEW YORK, Feb. 21, 2018 (GLOBE NEWSWIRE) — Eyenovia Inc. (“Eyenovia”), (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced that following discussions with the U.S. Food and Drug Administration (FDA), it has received clear feedback on its pivotal trial protocol design, as well as confirmation to advance its MicroPine therapeutic program for the treatment of progressive myopia into Phase III clinical development. Read more


January 2018

Eyenovia Announces Pricing of Initial Public Offering

NEW YORK, Jan. 25, 2018 (GLOBE NEWSWIRE) — Eyenovia Inc. (“Eyenovia”), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced the pricing of its initial public offering of 2,730,000 shares of common stock at a price of $10.00 per share.   Read more


January 2018

Eyenovia Announces Appointment of John Gandolfo as Chief Financial Officer

New York Eyenovia Inc., a clinical-stage ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class micro-therapeutics for the eye, today announced the appointment of John Gandolfo as Chief Financial Officer (CFO) effective December 18, 2017.   Read more


November 2017

American Academy of Ophthalmology Press Release on High-precision Micro-therapeutic Approach:  Wouldn’t it be Great if Eyedrops Didn’t Spill Out of Your Eyes?

New Orleans — A new kind of eyedropper can deliver tiny droplets of medication, treating the eye more precisely than traditional eyedroppers, while reducing waste and avoiding dangerous side effects. According to research presented today at AAO 2017, the 121st Annual Meeting of the American Academy of Ophthalmology, this technology may prove to be especially advantageous in the treatment of dry eye and glaucoma, for which patients require daily use of medicated eyedrops that can cost hundreds of dollars for a bottle that lasts only a month.  Read more


October 2017

Eyenovia Publication of EYE 102 Phase II Results Demonstrates Strong Pharmacodynamic Effect, Tolerability and Reduced Systemic Exposure of High- Precision Micro-dosing compared to Conventional Eyedroppers
New York – October 30, 2017 – Eyenovia Inc., a clinical-stage ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of potential first-in-class micro-therapeutics for the eye, today announced that the positive results of its EYE 102 Phase II study have been published online ahead of print in the peer-reviewed journal Therapeutic Delivery.  Read more


November 2016

Eyenovia, Inc. announces publication of Phase II study results demonstrating benefits of microformulation over conventional  eyedroppers and addition of scientific advisory board members
Eyenovia, Inc. announces publication of Phase II study results demonstrating benefits of microformulation over conventional eyedroppers and addition of scientific advisory board members Eyenovia’s study shows that conventional ophthalmic eye drops significantly overdose the eye and that equivalent, or greater, pharmacodynamic effect can be achieved with 80% less ocular exposure through Eyenovia’s ophthalmic microformulationProf. Robert N. Weinreb, Director, Shiley Eye Institute and Chair, Department of Ophthalmology, University of California San Diego and Prof. Louis Pasquale Director, Glaucoma Service, Massachusetts Eye and Ear and Professor of Ophthalmology, Harvard Medical School are joining Eyenovia’s scientific advisory board.  Read More


April 2015

Eyenovia Signs Asia Partnership
Eyenovia Signs Asia Partnership and Licensing Agreement with Senju Pharmaceuticals of Japan: Eyenovia Biopharma signs exclusive Asia license and development agreement for ophthalmic therapeutics based on proprietary microdrops technology. Under the terms of the development partnership agreement, Senju  acquires the exclusive rights to develop and commercialize microdosed  therapeutics in Japan and the rest of Asia, the fastest growing ophthalmic drugmarket in the world.  In addition to the licensing agreement, Senju is  also joining the Series A investment syndicate alongside Private Medical  Equity, Eshelman Ventures and Mario Family Partners. Senju will also assume  responsibility for all Asia R&D activities.  Read More


November 2014

Eyenovia expands Board
Eyenovia Expands Board: Dr. Fred Eshelman joins the Board of Directors of Eyenovia. Dr. Eshelman is a distinguished industry executive whose prior roles include founder and CEO of PPD and Chairman of Furiex Pharmaceuticals. Dr. Earnest Mario joins the Board of Directors of Eyenovia. Dr. Mario has held numerous executive roles in Bio-Pharma including CEO of Glaxo Holdings and Chairman and CEO of Alza Corporation and Reliant Pharmaceuticals.


October 2014

Eyenovia-Pointguard Partnership
Eyenovia enters into a development partnership agreement with Pointguard Partners. Pointguard Partners will be the preferred clinical development operations partner for Eyenovia. Technology acquisition and funding: Eyenovia completes acquisition of micro-droplet technology and intellectual property from Corinthian Ophthalmics. Eyenovia acquisition is simultaneous with the completion of a Series A financing led by Private Medical Equity.


September  2014

Microdroplet Technology Featured
Research on the Eyenovia technology was featured in the ophthalmic press following the presentation and best paper award at the American Academy of Ophthalmology.  Ophthalmology Times EyeWorld

 

June 2018

Eye drop makers are ripping you off
In May, the United States Supreme Court denied a request by some of the largest drug companies in the world, to block a patient lawsuit about the size of eye drops.
Read more 


Eyenovia receives patent for piezo-print technology features
Eyenovia Inc. has announced that two additional patent applications have received Notices of Allowance from the U.S. Patent and Trademark Office.
Read more 


Eyenovia receives Notices of Allowance on two patent applications
Eyenovia has received Notices of Allowance from the U.S. Patent and Trademark Office for two patent applications providing coverage on physiologic microdroplet ejection diameters and velocities, according to a press release.
Read more 


 

May 2018

CEO Sean Ianchulev Shares Eyenovia’s Plans to Replace Eye Drops with New Microdosing Technology
The last time we connected with Sean Ianchulev, MD, MPH, he shared Transcend’s ultimately winning story. Now, he’s the CEO and CMO of Eyenovia, a four-year-old company that’s developing a line of therapeutics for Glaucoma, Dry Eye, Mydriasis, and Myopia
Read more 


 

March 2018

Eyenovia myopia micro-therapy advances to phase 3 trial
The U.S. FDA has advanced Eyenovia Inc.’s therapeutic program for progressive myopia treatment, MicroPine, into phase 3 clinical development.
Read more 



February 2018

MicroPine phase 3 trial for myopia to begin in 2019
The MicroPine program for the treatment of progressive myopia will begin a phase 3 pivotal study in 2019, according to a press release from Eyenovia.
Read more 



January 2018

Chutes & Ladders – Pfizer oncology head Liz Barrett jumps ship to Novartis
Liz Barrett, currently Pfizer’s global president & GM of oncology, is behind the commercial success of cancer med Ibrance. Starting from Feb. 1, though, she’ll be working to drive sales of a direct competitor, Kisqali, as Novartis’ oncology head.
Read more 



November 2017

Wouldn’t it be Great if Eyedrops Didn’t Spill Out of Your Eyes?
New Orleans — A new kind of eyedropper can deliver tiny droplets of medication, treating the eye more precisely than traditional eyedroppers, while reducing waste and avoiding dangerous side effects. According to research presented today at AAO 2017, the 121st Annual Meeting of the American Academy of Ophthalmology, this technology may prove to be especially advantageous in the treatment of dry eye and glaucoma, for which patients require daily use of medicated eyedrops that can cost hundreds of dollars for a bottle that lasts only a month.  Read more 


Micro-dosing of phenylephrine comparable to conventional dropper administration
Piezo-ejection micro-dosing of phenylephrine showed comparable results to traditional eyedropper administration in pupil dilation, as well as less systemic absorption, according to a study.The phase 2, masked, nonrandomized, crossover study evaluated pupil dilation with topical phenylephrine in 12 eyes of 12 patients administered by a conventional 32-µL eyedropper (2.5% or 10% formulation) and in the second eye by an 8-µL electronic micro-dose ejection (10% formulation).  

Read more


Microdose Eye Droppers Cut Adverse Events, Costs
A microdose delivery system for eye drop therapies may be an improvement in treatment efficacy and costs.A study of microdose eye droppers, presented at the 121st Annual Meeting of the American Academy of Ophthalmology (AAO 2017) in New Orleans, LA, found that the dosing technology may better serve patients with dry eye (DE) and glaucoma.   Read more


Senators Move To Reduce ‘Colossal And Completely Preventable Waste’ Of Drugs
New York – November 1, 2017   ProPublica – Two U.S. senators introduced legislation Tuesday requiring federal agencies to come up with solutions to the waste caused by oversized eyedrops and single-use drug vials, citing a ProPublica story published last month  Read more


October 2017

Eyedrops Are Too Big, and It’s Costing Us Billions 
ProPublica –  October 18th , 2017 – When you put eyedrops in your eye and a bunch of the liquid spills out, that’s not necessarily user error. A ProPublica investigation part of the publication’s series on how billions of health care dollars are wasted each year finds that eyedrops are way too big—some of them more than twice what the eye can actually hold—resulting in drainage and waste.  Read More


 

American Academy of Ophthalmology 2017
Dr.Ianchulev, New York Eye and Ear Infirmary

Associate for Research in Vision and Ophthalmology 2016
Dr. Lin, UCSF

[email protected] Association for Cataract and Refractive Surgery 2016
Dr. LaBelle

International Symposium on Ocular Pharmacology
and therapeutics ISOPT 2015
B. Butler

American Academy of Ophthalmology 2014
Dr.Ianchulev

Therapeutic Delivery 2017
High-precision piezo-ejection ocular microdosing:
Phase II study on local and systemic effects of topical phenylephrine
Read More

 

Therapeutic Delivery 2016
Pharmacodynamic profile of mydriatic agents delivered by
ocular piezo-ejection microdosing compared with conventional eyedroppers.
Read More

Comparison Of Ocular Effects After Use Of Topical Eye Drops
Versus Use Of The WhisperTM Topical Drug Applicator
Read More